Carboplatin Versus Cisplatin in the Chemotherapy of Solid Tumors — Pro Carboplatin

  • David S. Alberts


The fact that we are still debating, in 1995, the merits of carboplatin versus cisplatin in the chemotherapy of solid tumors, exemplifies the extreme slowness of planning, implementing and completing important clinical trials in oncology. Cisplatin was approved for use in the treatment of ovarian cancer in the late 1970s, and carboplatin was approved for salvage therapy of ovarian cancer, in the late 1980s. Six years later, we continue to struggle with decisions concerning the appropriate role for these two platinum analogs in the management of ovarian, cervix, endometrial, head and neck, lung, and testicular cancers. Although there have been abundant phase III clinical trials comparing these agents in a number of target disease sites, the sample size and trial designs in most cases have proven inadequate to allow final conclusions to be drawn. Nevertheless, I have had no difficulty composing a “Pro Carboplatin” position paper. I even can say that this was a pleasurable experience!


Ovarian Cancer Endometrial Cancer Small Cell Lung Cancer Objective Response Rate Testicular Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    U.S.A. FDA approved package insert for Paraplatin (carboplatin for injection).Google Scholar
  2. 2.
    U.S.A. FDA approved package insert for Platinol (cisplatin for injection USP).Google Scholar
  3. 3.
    E. Witshaw. Ovarian trials at the Royal Marsden. Cancer Treat Rev, 12: 67–71 (suppl A). (1985).CrossRefGoogle Scholar
  4. 4.
    M. Adams, I.J. Kerby and I. Rocker, et al. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 28 (1): 57–60 (1989).CrossRefPubMedGoogle Scholar
  5. 5.
    C. Mangioni, G. Bolis and S. Pecorelli, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst, 81: 1464–72 (1989).CrossRefPubMedGoogle Scholar
  6. 6.
    K. Swenerton, J. Jeffrey and G. Stuart, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 10: 718–26 (1992).PubMedGoogle Scholar
  7. 7.
    W.W. Ten Bokkel Huinink, M.E.L. Van der Burg and A.T. Van Oosterom. et al. Carboplatin combination therapy for ovarian cancer. Cancer Treat Rep, 15 (8): 9–15 (1988).CrossRefGoogle Scholar
  8. 8.
    D.S. Alberts, S. Green and E.V. Hannigan, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase in randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706–17 (1992).PubMedGoogle Scholar
  9. 9.
    P.F. Conte, M. Bruzzone and F. Camino, et al. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide. A randomized trial in stage III–IV epithelial ovarian carcinoma. J Clin Oncol, 9: 658–63 (1991).PubMedGoogle Scholar
  10. 10.
    D. Belpomme, R. Bugat and M. Rives, et al. Carboplatin versus cisplatin in association with cyclophosphamide and doxorubicin as first line therapy in stage III–IV ovarian carcinoma: Results of an ARTAC phase III trial. Proc ASCO, 11:227(1992).Google Scholar
  11. 11.
    J.H. Edmonson, G.M. McCormack and H.S. Wieand, et al. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III–IV ovarian carcinoma. A comparison of equally myelosuppressive regimens. J Natl Cancer Inst, 81-1500–4 (1989).CrossRefPubMedGoogle Scholar
  12. 12.
    H. Gurney, D. Crowther and H. Anderson, et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann Oncol, 1:427–33 (1990).PubMedGoogle Scholar
  13. 13.
    T. Kato, H. Nishimura and T. Yamabe, et al. Phase III study of carboplatin for ovarian cancer. Japanese J of Cancer Chemother, 15: 2297–304 (1988).Google Scholar
  14. 14.
    K. Aabo, P. Adnitt, M, Adams, D.S. Alberts, et al. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. BMJ 303: 884–893 (1991).CrossRefGoogle Scholar
  15. 15.
    C.J. Williams, L. Steward and M. Parmar, et al. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. Semin Oncol, 19 (2): 120–8 (1992).PubMedGoogle Scholar
  16. 16.
    NIH Consensus Conference on Ovarian Cancer: Screening, Treatment and Follow-Up NIH Consensus Development Panel on Ovarian Cancer. JAMA, 273: 491–491, (1995).CrossRefGoogle Scholar
  17. 17.
    P.D. Bonomi, D.M. Finkelstein, J.C. Ruckdeschel, et al. Combination Chemotherapy versus Single Agents Followed by Combination Chemotherapy in Stage IV Non-Small Cell Lung Cancer: A Study of the Eastern Cooperative Oncology Group. J Clin Onc, 7:1602–1613, (1989).Google Scholar
  18. 18.
    J. Klastersky, J.P. Sculier, H. Lacroix, et al., Randomized Study Comparing Cisplatin or Carboplatin with Etoposide in Patients with Advanced Non-Small Cell Lung Cancer: European Organization for Research and Treatment of Cancer, Protocol 07861. J Clin Onc, 8:1556–1562, (1990).Google Scholar
  19. 19.
    P.A. Bunn, M. Cullen, M. Fukuoka, et al., Chemotherapy in Small Cell Lung Cancer: A Consensus Report. Lung Cancer, 5:127–134,(1989).CrossRefGoogle Scholar
  20. 20.
    P.A. Bunn, Clinical Experience with Carboplatin in Lung Cancers, Semin Oncol 19:1–11,(1992).PubMedGoogle Scholar
  21. 21.
    D.S. Bajorin, M.F. Sarosty, D.G. Pfeister, et al., Randomized of Etoposide and Cisplatin versus Etoposide and Carboplatin in Patients with Good-Risk Germ Cell Tumors: A Multi-institutional Study, J Clin One, 11:598–606, (1993).Google Scholar
  22. 22.
    Al-arafam, Semin Oncol, 21(5):28–34, (1994).Google Scholar
  23. 23.
    D.S. Alberts, D.J. Garcia. Salvage Chemotherapy in Recurrent or Refractory Squamous Cell Cancer of the Uterine Cervix. Semin Oncol, 21(4):37–46, (1994).PubMedGoogle Scholar
  24. 24.
    J.B. Green, S. Green, D.S. Alberts, et al. Carboplatin in Advanced Endometrial Cancer: A Southwest Oncology Group Phase II Study. In: Carboplatin JM-8: Current Prospective and Future Directions, P.A. Bunn, R. Canetta, R.F. Ozols, and M. Rozencweig (Eds). W.B. Saunders Company, pp. 113-121, (1990).Google Scholar
  25. 25.
    D. Alberts, E. Hannigan, R. Canetta, et al. Cisplatin versus carboplatin in advanced ovarian cancer? An economic analysis. Pharmacy & Therapeutics, 19: 692–706, (1994).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • David S. Alberts
    • 1
    • 2
  1. 1.Arizona Cancer CenterTucsonUSA
  2. 2.Southwest Oncology GroupGynecologic Cancer CommitteeSan AntonioUSA

Personalised recommendations